Daily Archives: 2012/02/22
Eylea Has Already Begun to Be Used by U.S. Retinal Specialists One Month Post-Launch, According to a Recent BioTrends Report
The LaunchTrends: Eylea Wave 1 report, which measures product uptake and commercial effectiveness at one month post launch, finds that 40% of surveyed retinal specialists have initiated trial on Regenerons Eylea, the newest treatment for wet age-related macular degeneration (wet AMD). One key advantage of Eylea over its main competitors, Genentechs Lucentis and Avastin, is the formal dosing schedule, which allows dosing every eight weeks following an initial three monthly doses...
The Molecular Basis Of Touch Sensation
A gene known to control lens development in mice and humans is also crucial for the development of neurons responsible for mechanosensory function, as neurobiologists of the Max Delbruck Center for Molecular Medicine (MDC) Berlin-Buch have now discovered. They found that in mice in which they had removed the c-Maf gene in the nerve cells, touch sensation is impaired...
AMD Update 17: Dame Judi Dench Has Macular Degeneration
Over the weekend, several articles appeared in the British press and also here in the States, about Dame Judi Dench announcing that she has macular degeneration – dry in one eye and wet in the other – and that she was going blind, although she was receiving treatment for the wet AMD in the hopes of preserving some of her sight in that eye.
I considered writing about this, but couldn’t find the right words – then I read what my friend Steve Rose of the Foundation Fighting Blindness had written on his blog, Eye on the Cure – and (Read more...)
Subscribe
